Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Two Out Of Three Ain't Bad: Biosimilar User Fee Talks Completed

This article was originally published in The Pink Sheet Daily

Executive Summary

Industry and FDA are in the process of ratifying the commitment letter for BsUFA II, leaving only the generic drug user fee program still ongoing.


Related Content

Jenkins' Retirement From US FDA Was Several Years In The Making
GDUFA II Will Include Small Business Relief, Priority ANDA Reviews
PDUFA VII Already: Could Breakthrough Ideas Apply Outside Program?
Generic User Fee Talks Reach 'Final Wording' But Still Not Done
GDUFA Negotiations Shift To 'Tiered' Fee Models
PDUFA Fees Forced Down For FY 2017 Due To Refund Provision
Sponsors, FDA Reviewers To Get More Flexibility Under New User Fee Program
FDA Meets ANDA Backlog Goal Early, Still Doesn't Feel Out Of Woods
Biosimilar User Fee Talks Begin With Industry Negotiating Amongst Itself


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts